flt3 ligand/anti-ctla-4 antibody/il-12 engineered oncolytic vaccinia virus rival-01
Generic: Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01
flt3 ligand/anti-ctla-4 antibody/il-12 engineered oncolytic vaccinia virus rival-01: 1 clinical trial tracked.
flt3 ligand/anti-ctla-4 antibody/il-12 engineered oncolytic vaccinia virus rival-01 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about flt3 ligand/anti-ctla-4 antibody/il-12 engineered oncolytic vaccinia virus rival-01, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Primary endpoint: Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) alone at each dose level
Interventionalopen27 targetStarted 2020-06Completion 2023-0111 sites · Canada, South Korea, United StatesTurnstone Biologics, Corp.